Group 1 - The company announced the approval of multiple proposals during the first meeting of the 11th Board of Directors in 2026, including the construction of the second phase of the oral liquid project by its wholly-owned subsidiary, Yunnan Baiyao Group Wenshan Qihua Co., Ltd., with a total investment budget of 137.36 million yuan [1] - The company approved the organizational structure plan for 2026 and appointed Dong Ming as CEO, Qian Yinghui as Board Secretary, and Li Mengjue as Securities Affairs Representative, with a three-year term [1] - The company aims to accelerate the establishment of a modern R&D system and capabilities, integrating traditional Chinese medicine with modern technology, by appointing Zhu Zhaoyun as the Strategic Scientist for Traditional Chinese Medicine and Zhang Ning as the Chief Scientist [1] Group 2 - Li Jin retired and will no longer serve as a senior management personnel of the company [1] - Zhu Zhaoyun is an academician of the Chinese Academy of Engineering and has held positions such as Director of Yunnan Provincial Institute of Drug Research and R&D Director of Yunnan Baiyao Group [1] - Zhang Ning is a professor at Peking University and has previously served as Deputy Director of the Medical Department at Peking University and Vice President of Tianjin Medical University [1]